Editorial Policy

We prioritize topics based on public interest, clinical relevance, and regulatory developments. We focus on compounds that people are actively researching — including GLP-1 medications, weight-loss peptides, recovery peptides, and longevity compounds — and on questions that patients commonly ask their healthcare providers. We also monitor PubMed, FDA communications, and ClinicalTrials.gov for emerging research and safety updates.

Every compound profile and comparison is built from primary sources. We begin with FDA labeling, safety communications, and regulatory databases. We then review clinical trial records from ClinicalTrials.gov and peer-reviewed publications indexed in PubMed. We prioritize systematic reviews and meta-analyses over individual studies, and we clearly distinguish between FDA-approved uses, off-label uses, investigational compounds, and research-only substances.

• FDA labels, safety communications, approval letters, and databases.
• ClinicalTrials.gov study records and published results.
• Peer-reviewed primary clinical trials in indexed journals.
• Systematic reviews and meta-analyses (e.g., Cochrane).
• Recognized health agencies: NIH, CDC, NLM, EMA, WHO.
• Professional medical guidelines from recognized societies.
• Manufacturer labeling only for factual product details — never as the sole basis for benefit claims.

• Anonymous peptide blogs or influencer posts.
• Vendor marketing materials or advertising.
• Social media anecdotes or forum posts.
• Affiliate content treated as clinical evidence.
• AI-generated citations that cannot be verified.
• Studies that cannot be located, read, and independently verified.

We assign evidence labels — not numerical scores in isolation — to help readers understand the strength of available research. Our labels include: Strong clinical evidence, Moderate clinical evidence, Preliminary human evidence, Preclinical evidence, Mechanistic hypothesis, Insufficient evidence, and Conflicting evidence. A high evidence rating requires well-designed human trials, consistent results across studies, and replication — not merely a large number of publications.

We may use AI tools to assist with drafting, summarizing, or organizing research. However, no content is published without human editorial review. AI-generated text is verified against primary sources, checked for accuracy, and revised for clarity and appropriate caution before publication. We never publish AI-generated medical claims without source verification.

Peptide Compass may earn affiliate revenue from vendor listings in the Marketplace. These relationships do not influence compound evidence scores, regulatory assessments, or editorial content. Vendors cannot pay to improve their evidence rating or to have negative information removed. Any paid placement is clearly labeled as "Featured" or "Sponsored."

High-risk pages — particularly those covering FDA-approved medications with active safety communications — are reviewed at least every 6 months, or immediately when significant regulatory or safety news emerges. All compound profiles are reviewed at least annually. Each page displays its last-reviewed date.